However, the Indian authorities expect domestic demand for this drug to grow and are in contact with remdesivir producers, the publication notes.
Remdesivir is an anti-COVID-19 medicine for adults and adolescents over 12 years of age who develop pneumonia and need oxygen support. On the other hand, data on the efficacy of this drug are contradictory.
Studies by the U.S. National Institute of Allergy and Infectious Diseases in 10 countries with more than a thousand patients showed that intravenous remdesivir accelerated the recovery process in hospitalized patients. However, a WHO study found that the use of remdesivir had no significant effect in reducing patient mortality and length of hospital stay.
The Indian health services announced earlier on Sunday that more than 152.8 thousand had been confirmed in the last day. new cases of coronavirus infection, and India currently outperforms the rest of the world in this incidence rate.
The number of COVID-19 cases per day in India has reached a new record six times this week. India now has one of six new cases of coronavirus detected worldwide per day. Mortality from the disease in India is now at its highest in more than five months.
India is an important supplier of vaccines to other countries, especially the poorer ones. Part of this production is supplied under the COVAX program, which provides vaccines to poor countries, led by the World Health Organization (WHO) and the GAVI, the vaccination alliance.